These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 26783311)

  • 1. Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.
    Lubeck DP; Danese MD; Duryea J; Halperin M; Tayama D; Yu E; Lalla D; Grotta JC
    Int J Stroke; 2016 Feb; 11(2):198-205. PubMed ID: 26783311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
    Adeoye O; Sucharew H; Khoury J; Tomsick T; Khatri P; Palesch Y; Schmit PA; Pancioli AM; Broderick JP;
    Stroke; 2015 Feb; 46(2):461-4. PubMed ID: 25523054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
    Yan X; Hu HT; Liu S; Sun YH; Gao X
    Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
    Fredwall M; Sternberg S; Blackhurst D; Lee A; Leacock R; Nathaniel TI
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2569-2574. PubMed ID: 27618196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
    Boudreau DM; Guzauskas GF; Chen E; Lalla D; Tayama D; Fagan SC; Veenstra DL
    Stroke; 2014 Oct; 45(10):3032-9. PubMed ID: 25190439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
    Soeteman DI; Menzies NA; Pandya A
    Value Health; 2017; 20(7):894-901. PubMed ID: 28712618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA.
    Dong Y; Cao W; Ren J; Nair DS; Parker S; Jahnel JL; Swanson-Devlin TG; Beck JM; Mathews M; McNeil CJ; Upadhyaya M; Gao Y; Dong Q; Wang DZ
    PLoS One; 2015; 10(8):e0131487. PubMed ID: 26247772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.
    Kamel H; Patel N; Rao VA; Cullen SP; Faigeles BS; Smith WS; Flint AC
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1111-6. PubMed ID: 23122722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
    Xian Y; Federspiel JJ; Grau-Sepulveda M; Hernandez AF; Schwamm LH; Bhatt DL; Smith EE; Reeves MJ; Thomas L; Webb L; Bettger JP; Laskowitz DT; Fonarow GC; Peterson ED
    JAMA Neurol; 2016 Jan; 73(1):50-9. PubMed ID: 26551916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
    Stroke; 2000 Dec; 31(12):2912-9. PubMed ID: 11108748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
    Alvarez-Sabín J; Molina CA; Montaner J; Arenillas JF; Huertas R; Ribo M; Codina A; Quintana M
    Stroke; 2003 May; 34(5):1235-41. PubMed ID: 12677014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience.
    Tanne D; Gorman MJ; Bates VE; Kasner SE; Scott P; Verro P; Binder JR; Dayno JM; Schultz LR; Levine SR
    Stroke; 2000 Feb; 31(2):370-5. PubMed ID: 10657408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke.
    Chalela JA; Kasner SE; Jauch EC; Pancioli AM
    Stroke; 1999 Nov; 30(11):2366-8. PubMed ID: 10548672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in neutrophils after recombinant tissue plasminogen activator thrombolysis predicts poor functional outcome of ischaemic stroke: a longitudinal study.
    Shi J; Peng H; You S; Liu Y; Xu J; Xu Y; Liu H; Shi R; Cao Y; Liu CF
    Eur J Neurol; 2018 Apr; 25(4):687-e45. PubMed ID: 29341345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Streamlined Hyperacute Magnetic Resonance Imaging Protocol Identifies Tissue-Type Plasminogen Activator-Eligible Stroke Patients When Clinical Impression Is Stroke Mimic.
    Goyal MS; Hoff BG; Williams J; Khoury N; Wiesehan R; Heitsch L; Panagos P; Vo KD; Benzinger T; Derdeyn CP; Lee JM; Ford AL
    Stroke; 2016 Apr; 47(4):1012-7. PubMed ID: 26892282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute ischemic stroke and long-term outcome after thrombolysis: nationwide propensity score-matched follow-up study.
    Schmitz ML; Simonsen CZ; Hundborg H; Christensen H; Ellemann K; Geisler K; Iversen H; Madsen C; Rasmussen MJ; Vestergaard K; Andersen G; Johnsen SP
    Stroke; 2014 Oct; 45(10):3070-2. PubMed ID: 25190440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computed Tomography Angiography in Acute Stroke Patients Receiving Recombinant Tissue Plasminogen Activator: Outcome and Safety Evaluations in an Asian Population.
    Lin CM; Wu HC; Wu YM; Liu CH; Chang KH; Chang TY; Huang KL; Chang YJ; Lee TH; Tsay PK; Cheng CK; Chang CH
    Cerebrovasc Dis; 2020; 49(1):62-69. PubMed ID: 32023610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
    Saver JL; Goyal M; Bonafe A; Diener HC; Levy EI; Pereira VM; Albers GW; Cognard C; Cohen DJ; Hacke W; Jansen O; Jovin TG; Mattle HP; Nogueira RG; Siddiqui AH; Yavagal DR; Devlin TG; Lopes DK; Reddy V; du Mesnil de Rochemont R; Jahan R;
    Int J Stroke; 2015 Apr; 10(3):439-48. PubMed ID: 25777831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.